Lumapil Forte Tablet (Anti-malaria) x6

Lumapil Forte Tablet is an antimalarial medication containing Artemether and Lumefantrine. This fixed-dose combination effectively treats acute uncomplicated Plasmodium falciparum malaria in adults and children weighing at least 35 kg.

Uses

Lumapil Forte treats acute uncomplicated malaria caused by Plasmodium falciparum, including multidrug-resistant strains. It’s recommended as first-line treatment for falciparum malaria in areas with chloroquine resistance. Lumapil Forte is suitable for both adults and children weighing 35 kg or more.

Benefits

• Provides rapid parasite clearance within 48-72 hours
• Effective against drug-resistant malaria strains
• Reduces fever and symptoms quickly
• High cure rates with low resistance development
• Prevents recrudescence with combination therapy
• Well-tolerated with minimal side effects
• Shorter treatment course improves compliance
• Reduces risk of severe malaria complications
• WHO-recommended first-line antimalarial therapy

How It Works

Artemether rapidly reduces parasite biomass by generating free radicals that damage parasite membranes and proteins. Lumefantrine has a longer half-life, eliminating residual parasites and preventing recurrence. This combination ensures complete parasite eradication while minimizing resistance development.

Dosage

Take with fatty food or milk to enhance absorption. Complete all six tablets even if symptoms improve.

Duration of Action

Lumapil Forte begins working within hours, with Artemether providing rapid initial parasite reduction. Fever typically subsides within 24-48 hours. Lumefantrine continues eliminating parasites for several days due to its longer half-life, providing sustained antimalarial activity for 2-3 weeks.

Side Effects

Most patients tolerate Lumapil Forte well. Common side effects include headache, dizziness, nausea, and fatigue. Some experience abdominal pain, diarrhea, or loss of appetite. Mild sleep disturbances or weakness may occur but typically resolve after treatment completion.

Warning

Complete the full 6-tablet course to prevent treatment failure and resistance development. Lumapil Forte may cause QT interval prolongation in susceptible patients. Avoid in patients with severe cardiac conditions or electrolyte imbalances. Seek immediate medical attention for persistent vomiting, convulsions, or signs of severe malaria.

Pregnancy and Breastfeeding

Lumapil Forte is safe during second and third trimesters of pregnancy when benefits outweigh risks. Use in first trimester only when no safer alternatives exist. Limited data available for breastfeeding, but benefits typically outweigh potential risks in malaria treatment.

Interaction

• May increase QT prolongation risk with certain cardiac medications
• Possible reduced effectiveness with rifampin and anticonvulsants
• May interact with some antiretroviral drugs
• Grapefruit juice may affect drug metabolism
• Potential interaction with other antimalarial medications

Precaution

Use cautiously in patients with cardiac arrhythmias, liver impairment, or electrolyte disturbances. Monitor patients with severe kidney disease. Ensure proper malaria diagnosis before treatment when possible. Take with food to maximize absorption and effectiveness of Lumapil Forte.

Important Information

Lumapil Forte does not prevent malaria transmission or reinfection. Continue using protective measures against mosquito bites. If vomiting occurs within one hour of taking a dose, repeat that dose. Store below 25°C in original packaging. Consult healthcare provider if symptoms worsen or persist after completing the course.